Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 24265411)

1.

Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects.

Krieckaert CL, Nair SC, Nurmohamed MT, van Dongen CJ, Lems WF, Lafeber FP, Bijlsma JW, Koffijberg H, Wolbink G, Welsing PM.

Ann Rheum Dis. 2015 Feb;74(2):361-8. doi: 10.1136/annrheumdis-2013-204101. Epub 2013 Nov 21.

PMID:
24265411
2.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

4.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

5.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

6.

The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.

Benucci M, Li Gobbi F, Sabadini L, Saviola G, Baiardi P, Manfredi M.

Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):1147-52.

PMID:
20074482
7.

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.

Bansback NJ, Brennan A, Ghatnekar O.

Ann Rheum Dis. 2005 Jul;64(7):995-1002. Epub 2004 Nov 18.

8.

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.

Cochrane Database Syst Rev. 2014 Sep 29;9:CD010455. doi: 10.1002/14651858.CD010455.pub2. Review.

PMID:
25264908
9.
10.

Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.

Nguyen CM, Bounthavong M, Mendes MA, Christopher ML, Tran JN, Kazerooni R, Morreale AP.

Pharmacoeconomics. 2012 Jul 1;30(7):575-93. doi: 10.2165/11594990-000000000-00000. Review. Erratum in: Pharmacoeconomics. 2012 Nov 1;30(11):1096.

PMID:
22640174
11.

An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.

Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM, Anis AH, Marra CA.

Drugs. 2005;65(4):473-96. Review.

PMID:
15733011
12.
13.

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C.

Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060. Review.

14.

Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.

Schipper LG, Kievit W, den Broeder AA, van der Laar MA, Adang EM, Fransen J, van Riel PL.

Rheumatology (Oxford). 2011 Jul;50(7):1320-30. doi: 10.1093/rheumatology/ker084. Epub 2011 Mar 2.

15.

[Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].

Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.

Z Rheumatol. 2004 Feb;63(1):59-75. German.

PMID:
14991279
16.

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.

Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.

Pharmacoeconomics. 2005;23(4):395-420.

PMID:
15853438
18.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

19.

Economic evaluation of arthritis self management in primary care.

Patel A, Buszewicz M, Beecham J, Griffin M, Rait G, Nazareth I, Atkinson A, Barlow J, Haines A.

BMJ. 2009 Sep 22;339:b3532. doi: 10.1136/bmj.b3532.

20.

Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy.

Diamantopoulos A, Benucci M, Capri S, Berger W, Wintfeld N, Giuliani G, Ricciardi W.

J Med Econ. 2012;15(3):576-85. doi: 10.3111/13696998.2012.665110. Epub 2012 Mar 9.

PMID:
22313326
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk